Abaris Investment Management AG recently announced the acquisition of new stake in iHuman Inc. (NYSE:IH). The institutional investor has increased its shareholding in the Consumer Defensive company by 583.33% to 0.2 million shares with purchase of 0.17 million shares. This fresh investment now brings its stake to 0.84% valued currently at $0.53 million. In addition, SSgA Funds Management, Inc. raised its holdings by 990.0 to 17989.0 shares. And GVC Gaesco Gestión SGIIC SA has lifted its position by 0.18% or 33.0 shares – to 18043.0 shares.
With over 0.1 million iHuman Inc. (IH) shares trading Tuesday and a closing price of $3.44 on the day, the dollar volume was approximately $0.35 million. The shares have shown a positive half year performance of 38.15% and its price on 01/24/23 lost nearly -6.52%. Currently, there are 53.24M common shares owned by the public and among those 24.46M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 1 analysts who have offered their price forecasts for IH have a consensus price objective of $21.61. The analysts have set the share’s price value over the next 12 months at a high of $21.61 and a low of $21.61. The average price target is -10.97% below its recent price level and an upside to the estimated low will see the stock gain 84.08% over that period. But an upside of 84.08% will see the stock hit the forecast high price target while median target price for the stock is $21.61.
The top 3 mutual fund holders in iHuman Inc. are Abaris Technology Opportunities, Haas invest4 innovation, and Abaris Defensive Equity. Abaris Technology Opportunities owns 0.17 million shares of the company’s stock, all valued at over $0.46 million. The company bought an additional 0.17 million shares recently to bring their total holdings to about 0.72% of the shares outstanding. Abaris Defensive Equity now owns shares totaling to 0.12% of the shares outstanding.
Shares of iHuman Inc. (NYSE: IH) opened at $3.66, down -$0.02 from a prior closing price of $3.68. However, the script later moved the day high at 3.7700, down -6.52%. The company’s stock has a 5-day price change of -6.78% and 82.01% over the past three months. IH shares are trading 32.31% year to date (YTD), with the 12-month market performance up to 28.84% higher. It has a 12-month low price of $1.10 and touched a high of $4.26 over the same period. IH has an average intraday trading volume of 43.43K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 6.47%, 36.03%, and 45.04% respectively.
Institutional ownership of iHuman Inc. (NYSE: IH) shares accounts for 14.00% of the company’s 53.24M shares outstanding. Mutual fund holders own 1.37%, while other institutional holders and individual stakeholders account for 13.37% and — respectively.
It has a market capitalization of $184.69M. The stock’s trailing 12-month PE ratio is 19.01, while the earnings-per-share (ttm) stands at $0.18. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.21% over the week and 17.29% over the month.
Analysts forecast that iHuman Inc. (IH) will achieve an EPS of $0 for the current quarter, $0 for the next quarter and $0.18 for 2022. The lowest estimate earnings-per-share for the quarter is $0 while analysts give the company a high EPS estimate of $0.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 1 brokerage firm advisors rate iHuman Inc. (IH) as a “Strong Buy” at a consensus score of 1.00. Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 0 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the IH, a number of firms have released research notes about the stock. Citigroup stated their Buy rating for the stock in a research note on December 30, 2022, with the firm’s price target at $3.10.